^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tolsura (SUBA-itraconazole)

    i
    Other names: SUBA-Cap
    Associations

    News

    Trials
    Company:
    Inhibitor Therap, Mayne Pharma
    Drug class:
    Hedgehog cell-signalling pathway inhibitor
    Related drugs:
    Associations

    News

    Trials
    27d
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Active, not recruiting, Kura Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • MEIS1 (Meis Homeobox 1)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)
    2ms
    Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Feb 2030 | Trial primary completion date: Jan 2028 --> Feb 2030
    Trial completion date • Trial primary completion date
    |
    itraconazole • Tolsura (SUBA-itraconazole)
    3ms
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=453, Recruiting, Pfizer | Trial completion date: Mar 2029 --> Jul 2029
    Trial completion date
    |
    enzalutamide • Onmel (itraconazole) • Tolsura (SUBA-itraconazole) • mevrometostat (PF-06821497)
    12ms
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Recruiting, Kura Oncology, Inc. | N=199 --> 263
    Enrollment change
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)
    over2years
    HITMAN: Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, St Vincent's Hospital, Sydney | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    hydroxychloroquine • Tolsura (SUBA-itraconazole)
    almost6years
    Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) (clinicaltrials.gov)
    P2b, N=38, Completed, HedgePath Pharmaceuticals, Inc. | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    GLI1 (GLI Family Zinc Finger 1)
    |
    GLI1 expression
    |
    Tolsura (SUBA-itraconazole)